Novartis | NVS - Interest Expense On Debt

Stock Price
148.08
Daily Change
-1.76 -1.17%
Monthly
-1.15%
Yearly
35.13%
Q2 Forecast
145.02

Novartis reported $281M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Amgen USD 657M 4M Mar/2026
AstraZeneca USD 484M 181M Dec/2025
Bausch Health Companies USD 397M 15M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Canopy Growth CAD 7.34M 1.46M Dec/2025
Corcept Therapeutics USD 814.88M 809.46M Mar/2026
Drreddys Laboratories INR 944M 127M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
J&J USD 43M 25M Mar/2026
Merck USD 479M 67M Mar/2026
Novartis USD 343M 39M Mar/2026
Novartis USD 281M 8M Sep/2025
Pacira USD 3.7M 193K Mar/2026
Perrigo USD 7.98B 7.94B Mar/2026
Pfizer USD 671M 40M Mar/2026
Phibro Animal Health USD 11.91M 191K Dec/2025
Prestige Brands USD 10.67M 636K Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 178M 203M Mar/2026
Sanofi EUR -25M 99.78M Dec/2025
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Zoetis USD 62M 5M Mar/2026